---
title: "Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295833036.md"
description: "Clearmind Medicine (NASDAQ: CMND) has advanced its CMND-100 clinical trial for Alcohol Use Disorder to Parts B and C after the Data and Safety Monitoring Board approved the move following positive Phase A safety results. Part B will test the drug on patients with moderate to severe AUD, while Part C involves healthy volunteers. The stock rose 9.09% to $1.80."
datetime: "2026-08-13T18:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295833036.md)
  - [en](https://longbridge.com/en/news/295833036.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295833036.md)
---

# Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

The independent Data and Safety Monitoring Board on Thursday unanimously approved **Clearmind Medicine Inc.** (NASDAQ:CMND) to advance its ongoing FDA-regulated Phase 1/2 clinical trial.

The study evaluates CMND-100, a clinical candidate aimed at treating Alcohol Use Disorder (AUD), in Parts B and C of the trial.

The progression follows the successful conclusion of Part A. In that initial phase, CMND-100 achieved its primary safety endpoint, displaying a positive safety and tolerability profile across all planned dose levels in healthy individuals.

After a thorough review of the safety dataset, the board recommended moving forward with the previously approved study protocol.

**Read Also: Why Is Clearmind Medicine Stock Sliding On Wednesday?**

## Transitioning To Patient Testing

Part B serves as a critical clinical milestone for the biotech company, which focuses on non-hallucinogenic therapeutics for under-treated health issues like addiction and weight loss.

For the first time, CMND-100 will be tested on patients actively suffering from moderate to severe AUD.

Researchers will sequentially enroll two groups of six patients to receive 80 mg and 160 mg doses. This phase will evaluate safety, tolerability, and early clinical activity, notably the drug’s potential to decrease alcohol consumption and suppress cravings.

Simultaneously, Part C will involve healthy volunteers receiving a fixed daily dose of 160 mg over five consecutive days. This double-blind, placebo-controlled section is intended to define the drug’s safety profile further.

## Scalable, Non-Hallucinogenic Approach

CMND-100 is a proprietary oral formulation of MEAI (5-methoxy-2-aminoindane).

As a neuroplastogen-derived candidate, it promotes adaptive neuroplasticity without triggering the perceptual effects seen in classical psychedelics.

This supports a scalable treatment model that successfully avoids the need for prolonged monitored sessions or intensive clinical supervision.

**CMND Price Action:** Clearmind Medicine shares were up 9.09% at $1.80 at the time of publication on Thursday. The stock is trading near its 52-week low of $1.43, according to Benzinga Pro data.

**Read Also: Consumers Are Cutting Back — But Birkenstock Says Demand Is Still Running Strong**

_Image via Nicole Hester via Imagn Images_

### Related Stocks

- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)
- [BIRK.US](https://longbridge.com/en/quote/BIRK.US.md)

## Related News & Research

- [Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestone](https://longbridge.com/en/news/295791823.md)
- [Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint | CMND Stock News](https://longbridge.com/en/news/295792376.md)
- [Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout](https://longbridge.com/en/news/295112548.md)
- [Clearmind reports positive safety, tolerability in CMND-100 Phase I/II trial Part A dose escalation](https://longbridge.com/en/news/294366720.md)
- [16:13 ETCHICAGO-BORN SPORTSBALLER LAUNCHES A NEW KIND OF NON-ALCOHOLIC COCKTAIL--MADE FOR ATHLETES AND THE WAY THEY CELEBRATE](https://longbridge.com/en/news/296531689.md)